June 10, 2022
Japan needs to drastically reconsider whether it should continue to implement so-called “off-year” drug price revisions, Masatomi Akana, chair of the Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) drug pricing committee, reiterated on June 6. The off-year re-pricing “needs...read more